| Literature DB >> 35906244 |
Mariana F Tioni1, Robert Jordan2,3, Angie Silva Pena2, Aditya Garg2, Danlu Wu2, Shannon I Phan2, Christopher M Weiss2, Xing Cheng2, Jack Greenhouse4, Tatyana Orekov4, Daniel Valentin4, Swagata Kar4, Laurent Pessaint4, Hanne Andersen4, Christopher C Stobart5, Melissa H Bloodworth6, R Stokes Peebles6,7, Yang Liu8, Xuping Xie8, Pei-Yong Shi8, Martin L Moore2, Roderick S Tang2.
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of the COVID-19 global pandemic. SARS-CoV-2 is an enveloped RNA virus that relies on its trimeric surface glycoprotein spike for entry into host cells. Here we describe the COVID-19 vaccine candidate MV-014-212, a live, attenuated, recombinant human respiratory syncytial virus expressing a chimeric SARS-CoV-2 spike as the only viral envelope protein. MV-014-212 was attenuated and immunogenic in African green monkeys (AGMs). One mucosal administration of MV-014-212 in AGMs protected against SARS-CoV-2 challenge, reducing by more than 200-fold the peak shedding of SARS-CoV-2 in the nose. MV-014-212 elicited mucosal immunoglobulin A in the nose and neutralizing antibodies in serum that exhibited cross-neutralization against virus variants of concern Alpha, Beta, and Delta. Intranasally delivered, live attenuated vaccines such as MV-014-212 entail low-cost manufacturing suitable for global deployment. MV-014-212 is currently in Phase 1 clinical trials as an intranasal COVID-19 vaccine.Entities:
Year: 2022 PMID： 35906244 PMCID： PMC9334537 DOI： 10.1038/s41541-022-00509-6
Source DB: PubMed Journal: NPJ Vaccines ISSN： 2059-0105 Impact factor: 9.399